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Abstract
Advanced glycation endproducts (AGEs) are primarily known as a
complication in diabetic patients through their mediation of the
inflammatory response. However, a variety of studies have
demonstrated enhanced formation of AGEs in cardiovascular
disorders. Despite the large number of AGEs produced during the
Maillard reaction, recent focus is on the major non-crosslinking
AGE Nε-carboxymethyllysine. Kneyber and colleagues focused on
sepsis-induced cardiac dysfunction and investigated whether
myocardial inflammation is associated with enhanced cardiac AGE
deposition and whether this is further enhanced by mechanical
ventilation. They showed that both conditions are associated with
enhanced AGE deposition and myocardial inflammation. Therefore,
AGEs may participate in the inflammatory response related to
cardiac dysfunction in critically ill patients. Moreover, life-saving
ventilation stimulates AGE formation in these patients. This
interesting study raises the question of whether AGEs in critically ill
patients are a driving force of the disease.
Advanced glycation endproducts
The advanced glycation endproduct (AGE) Nε-carboxy-
methyllysine (CML), as recently investigated by Kneyber and
colleagues [1], can be formed either from glucose via
ketoamine or glyoxal or from lipids by oxidation via glyoxal.
This may explain why the pathophysiological role of AGEs is
not restricted to diabetes, in which condition they have been
primarily studied [2].
The enhanced formation of AGEs results in enhanced urinary
excretion. In this context, renal-insufficient patients have been
associated with CML values several times higher than in
healthy controls. Accumulating AGEs can be observed
histologically as endothelial depositions in atherosclerotic
plaques and tubular cells [3-5]. Their deposition initiates
increased NADPH oxidase and nuclear factor κB activity as
well as a reduction in endothelial nitric oxide synthase activity
[6]. These major effects cause inflammatory changes,
extracellular matrix accumulation and endothelial dysfunction.
Therefore, AGE accumulation is a potential target for treating
inflammatory diseases.
AGEs in sepsis and during mechanical
ventilation
The new and interesting idea of Kneyber and colleagues was
to investigate the association of CML with myocardial
inflammation during sepsis and the clinically relevant state of
mechanical ventilation, which by itself is known to induce AGE
accumulation in the lungs. This is of relevance as sepsis-
induced cardiac dysfunction is a frequent complication
associated with increased mortality. Therefore, they focused on
a situation where AGE accumulation is increased by systemic
inflammation and exacerbated by mechanical ventilation. The
association of CML with myocardial inflammation in sepsis and
mechanical ventilation is intriguing. Indeed, sepsis enhances
CML deposition, which is further aggravated by mechanical
ventilation. Thus, the myocardial deposition of AGEs is
associated with the disease and the therapeutic approach of
mechanical ventilation perpetuates AGE formation.
Opposing AGE effects in cardiovascular
animal models
These results raise the question, however, whether the
association reflects a relevant pathophysiological mechanism
or ‘only’ reflects the critical disease state. In the former case,
interfering with the production or accumulation of AGEs
could provide possible treatments. One option is to
administer soluble RAGE - the extracellular ligand-binding
domain of RAGE, the AGE receptor - which binds AGEs and
thereby limits the deleterious effects of AGEs. In animal
experiments, treatment with soluble RAGE ameliorated
inflammation and significantly reduced the atherosclerotic
lesion area in a glycemia- and lipid-independent manner [7].
Commentary
Advanced glycation endproducts in sepsis and mechanical
ventilation: extra or leading man?
Marcus Baumann
Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str. 22, 81675 Munich, Germany
Corresponding author: Marcus Baumann, marcus.baumann@lrz.tum.de
Published: 14 July 2009 Critical Care 2009, 13:164 (doi:10.1186/cc7939)
This article is online at http://ccforum.com/content/13/4/164
© 2009 BioMed Central Ltd
See related research by Kneyber et al., http://ccforum.com/content/13/3/R87
AGE = advanced glycation endproduct; CML = Nε-carboxymethyllysine.Critical Care    Vol 13 No 4 Baumann
Page 2 of 2
(page number not for citation purposes)
Another pharmacological option is blockade of AGE forma-
tion by substances such as aminoguanidine or pyridoxamine.
These have also been proven to prevent age-related cardiac
hypertrophy in the absence of changes in collagen and
elastin content [8] and diabetic complications in animal
models [9]. These different approaches to treat AGE accu-
mulation and the pathophysiological relevance of AGE
formation in sepsis and mechanical ventilation need to be
addressed in future studies using either soluble RAGE or
blockers of AGE formation.
AGEs in human cardiovascular disorders
Several cross-sectional studies have documented that AGE-
induced inflammation is also present in human diseases with
chronic low-grade inflammation and has also been associated
with diabetic microangiopathy [10], endothelial dysfunction
[11], atherosclerosis [3] and chronic heart failure [12].
However, in a prospective substudy of the Irbesartan Type 2
Diabetic Nephropathy Trial (IDNT) cohort including 450
patients with nephropathy caused by type 2 diabetes, CML
was not predictive for cardiovascular events [13]. Therefore,
it remains uncertain whether CML is of cardiovascular
relevance in humans.
Conclusions and outlook
Kneyber and colleagues present an interesting association
between a major non-cross-linking AGE and sepsis com-
bined with mechanical ventilation. Whether this association
reflects a pathophysiologically relevant characteristic needs
to be investigated in future studies. However, if interventional
studies demonstrate positive effects in animal models, the
availability of safe and cheap agents may offer an opportunity
to target myocardial inflammation in sepsis and mechanical
ventilation.
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